Ecopipam is a first-in-class selective dopamine D1 receptor antagonist with positive Phase 3 data in pediatric Tourette syndrome. No approved D1-selective treatments currently exist. Teva CEO called it "Pivot to Growth strategy in action." Jefferies called it Teva's largest deal in a decade. NDA submission anticipated H2 2026.

Nearly double Q1 2025 ($44.4B). Structural drivers: patent cliff creating $320B revenue exposure by 2030, deep cash reserves, attractive biotech valuations, wave of positive Phase 3 readouts. Three analysts, four investors, and a banker told Reuters the surge is "broader and more durable than just a rebound."

5x gap vs oral Wegovy in Week 2 spooked investors. CEO Ricks cited 20,000+ patients but IQVIA not capturing LillyDirect and telehealth volume (~35% of launch). Revised 2026 estimates: $1.3B-$1.7B, down from initial $4B-$5B. Needs to triple weekly run rate to hit low end. T2D filing late Q2 confirmed.

RTCT fundamentally changes clinical trial operations — sponsors submit data to FDA in real time during the trial rather than at the end. AstraZeneca and Amgen are pilot participants. This will reshape data management, regulatory strategy, and CRO operations.

Purdue permanently ceased operations following Chapter 11 conclusion. Knoa Pharma began operations as successor focused on safe access to critical medicines and supporting communities affected by the opioid crisis. Greenfield corporate build.

Mid-cap pharma entry into rare disease M&A. Chiesi building rare disease portfolio through acquisition. Ekterly positioned as oral alternative in HAE market dominated by injectables.

AbbVie expanding oncology pipeline via KRAS. Option structure suggests phased development with milestone-based commitment. KRAS space heating up with Revolution Medicines ASCO plenary May 31.

Lilly entering gene editing via AI-native approach. Profluent uses large language models to design novel gene editing proteins. Signals big pharma conviction in AI-designed therapeutics moving toward clinical programs.

Full Phase 3 RASolute 302 data in plenary session. Previously reported: 13.2 months median OS vs 6.7 months, HR 0.40. CNPV NDA filing expected H2 2026. Post-ASCO data drops historically trigger new clinical program initiations within 60 days.

The biotech IPO window has reopened at scale. Six companies have raised $300M+ in 2026 IPOs. Post-IPO companies typically expand headcount 30-50% within 12 months and deploy capital primarily toward clinical development.

Medicare GLP-1 bridge targets Foundayo at $50/month — massive volume expansion if implemented. Section 232 tariffs hit large pharma July 31, all others Sept 29. Companies need pricing strategy and supply chain restructuring.

Lilly is the most active acquirer in biopharma. Six deals in 2026 spanning gene editing, neuroscience, obesity, and oncology. $19.8B Q1 revenue beat estimates by $2B+. GLP-1 franchise at $12.8B/quarter. Deep cash position enables continued M&A through year-end.

UCB enters the cell therapy space through Neurona acquisition. Signals mid-cap pharma companies are now competing for cell therapy assets alongside mega-cap buyers. UCB's neuroscience focus creates a clear clinical development path for Neurona's platform.

Boehringer/Zealand report positive Phase 3 obesity data, establishing a third serious competitor in the GLP-1 space alongside Lilly and Novo. The obesity market is expanding beyond a two-player duopoly, creating new commercial infrastructure needs.

Novartis missed Q1 expectations as Entresto revenue declined 42% due to biosimilar competition. The miss validates the patent cliff thesis driving M&A across the industry. Novartis has $53B in cash reserves and will need to deploy aggressively to replace lost Entresto revenue.